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ABSTRACT The adrenergic system plays a
major role in the regulation of the uterine contractility
during pregnancy. Our previous studies have shown
the significance of the a1-adrenergic receptors (ARs) in
the control of pregnant uterine contractility both in vitro
and in vivo. Our present aim was to determine the
changes in mRNA expression and pharmacological
reactivity of the a1-ARs on days 18, 20, and 22 of
pregnancy. To demonstrate the expressions of a1-AR
subtype mRNA, we used a reverse transcription-poly-
merase chain reaction (RT-PCR); the pharmacological
reactivity was tested by electric field stimulation (EFS).
The expression of a1A-AR mRNA increased from day
18 to 22, while no a1B-AR mRNA was detectable. We
found a small increase in the expression of a1D-AR
mRNA on day 20, which was not followed by a signi-
ficant change in pharmacological reactivity. The a1D-
receptor expression and pharmacological reactivity
decreased significantly up to day 22. EFS studies re-
vealed that the a1A-AR antagonist 5-methylurapidil
had EC50 values (1.9106–6.3106 M) about
one order of magnitude lower than those of the a1D-AR
antagonistBMY7378(4106–3.6105M).How-
ever, the a1B-AR antagonist cyclazosine exerted only a
slight effect on the stimulated contractions. Strong
correlations were found between the a1A-mRNA expres-
sion and the EC50 of 5-methylurapidil (r2¼0.9712),
and between the a1D-AR mRNA expression and the
EC50 of BMY 7378 (r2¼0.9937). Our findings sug-
gest that both a1A- and a1D-ARs are involved in the
regulation of the pregnant uterine contractility. The
density and pharmacological reactivity indicate that
the a1A-AR seems to play the major role in late-preg-
nant myometrial contraction. Mol. Reprod. Dev. 62:
343–347, 2002.  2002 Wiley-Liss, Inc.
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INTRODUCTION
The a1-type of adrenergic receptors (ARs) plays a
critical role in the regulation of the sympathetic ner-
vous system. Cloning and pharmacological data have
revealed that the a1-ARs can be classified into the three
subtypes: a1A-, a1B-, and a1D-ARs (Hieble et al., 1995).
The a1-AR subtypes are the prime mediators of smooth
muscle contraction and hypertrophic growth (Piascik
and Perez, 2001).
The adrenergic system plays an important role in the
regulation of the uterine motor activity (Borda et al.,
1997). Contraction is mediated by the a-ARs in the
uterine smooth muscle (Hoffman et al., 1981; Rexroad,
1981). This provides a theoretical possibility for the use
of a1-AR blockers as tocolytic agents. The b-ARs are
involved in uterine relaxation (Levin et al., 1980;
Tanfin-Tougui et al., 1981), which is reflected in clinical
practice by the frequent application of b2-agonists as
tocolytic agents. The use of b2-mimetics, however,
results in many side-effects, such as tachyphylaxis,
tachycardia, pulmonary edema, hypokalemia, sodium
retention, and glucose intolerance (Canadian Preterm
Labour Investigators Group, 1992; Smigaj et al., 1998).
In earlier experiments, it was proved that an a-AR
antagonist induced a significant decrease in uterine
activity in the rat both in vitro and in vivo (Zupko´ et al.,
1997; Ga´spa´r et al., 1998). Additionally, at the end of
pregnancy the a1/b-AR ratio of the rat uterus was found
to be increased, in parallel with an increase in contra-
ctility, demonstrating a very close correlation with the
density of a1-ARs during rat pregnancy (Zupko´ et al.,
1998). Moreover, a a1A-AR knock-down transformed
post-partum animal model was set up with antisense
oligodeoxynucleotides in order to prove the crucial role
of the a1A-ARs in uterine contractility (Ducza et al.,
2001).
Despite these facts, knowledge relating to the changes
in a1-AR subtype density during pregnancy is limited.
Our present aim was to determine the changes in
density and pharmacological reactivity of the a1-ARs
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subtypes in late-pregnant rats. To demonstrate the
expressions of a1-AR subtype mRNA, we used a reverse
transcription-polymerase chain reaction (RT-PCR) on
days 18, 20, and 22. Electric field stimulation (EFS) was
applied to test the pharmacological reactivity of the rat
uterus in late pregnancy.
MATERIALS AND METHODS
Animal investigations were carried out with the ap-
proval of the Ethical Committee for Animal Research,
University of Szeged (registration number: 23/1999).
Mating of the Animals
Mature female (180–200 g) and male (240–260 g)
Sprague–Dawley rats were mated in a special mating
cage. A metal door, movable by a small electric engine,
separated the rooms for themale and female animals. A
timer controlled the function of the engine. Since rats
are usually active at night, the separating door was
opened before dawn. Within 4–5 hr after the possibility
of mating, vaginal smears were taken from the female
rats, and a sperm search was performed under a micro-
scope at a magnification of 1200 times. If the search
proved positive, or when smear taking was impossible
because of an existing vaginal sperm plug, the female
rats were separated and were regarded as first-
day pregnant animals.
RT-PCR Studies
Tissue isolation. Female Sprague–Dawley rats
(250–300 g) were anesthetized with sodium pentobar-
bital (1 g/kg i.p.). Uterus tissues from nonpregnant
animals and on gestational days 18, 20, and 22 were
rapidly removed and dissected in ice-cold saline (0.9%
NaCl) containing 2 U/ml of recombinant ribonuclease
inhibitor (RNasin, Promega, Southampton, UK) The
tissues were frozen in liquid nitrogen and then stored at
708C until total RNA extraction.
Total RNA preparation. Total cellular RNA was
isolated by extraction with guanidinium thiocyanate-
acid-phenol-chloroform according to the procedure of
Chomczynski and Sacchi (1987). After precipitation
with isopropanol, the RNAwas treated with RNase-free
DNase I for 30 min at 378C, re-extracted with phenol,
precipitated with ethanol, washed with 75% ethanol,
and then resuspended in diethyl pyrocarbonate-treated
water, and the RNA concentration was determined by
optical density measurements at 260 nm.
RT-PCR. The RNA (0.5 mg) was denatured at 708C
for 5 min in a reaction mixture containing 20 U of
RNase inhibitor (Hybaid Corp.,Middlesex, UK), 200 mM
dNTP (Sigma-Aldrich, Budapest, Hungary), 20 mM
oligo(dT) (Hybaid Corp.) in 50 mM Tris-HCl, pH 8.3,
75 mMKCl, and 5 mMMgCl2 in a final reaction volume
of 19 ml. After the mixture had been cooled to 48C, 20 U
of M-MLV reverse transcriptase, RNase H Minus
(Promega) was added, and the mixture was incubated
at 378C for 60 min and then at 728C for 10 min.
The PCR was carried out with 5 ml cDNA, 25 ml
ReadyMix REDTaq PCR reaction mix (Sigma-Aldrich)
and 50 pm sense and antisense primer. The primer
sequences used to amplify the a1A-AR were 50-GTA
GCC AAG AGA GAA AGC CG-30 (for the forward
primer) and 50-CAA CCC ACC ACG ATG CCC AG-30
(for the reverse primer); these primers were anticipated
to generate 212 bp PCR product. For rat a1B-AR cDNA,
a 300 bp PCR product resulted with forward primer
50-GCT CTT CTA CAT CCC GCT CG-30 and reverse
primer 50-AGGGGAGCCAACATAAGATGA-30. The pri-
mers for the a1D-AR were 50-CGT GTG CTC CTT CTA
CCT ACC-30 (for the forward primer) and 50-GCA CAG
GAC GAA GAC ACC CAC-30 (for the reverse primer)
(Scofield et al., 1995). A rat GAPDH probe was used
as internal control in all samples (Tso et al., 1985).
The PCR was performed with a PCR Sprint thermal
cycler (Hybaid Corp.), with the following cycle para-
meters: after initial denaturation at 958C for 3 min, the
reactions were taken through 35 cycles of 1 min at
948C, 1 min annealing at 548C (a1B- and a1D-AR) or
508C (a1A-AR), and 728C for 2 min. After the last cycle,
incubation was continued for 10 min at 728C, followed
by lowering of the temperature to 48C. a-32P-dCTP
(1 mCi) was added to the above reaction mixture to
quantify the amplified product. PCR products were
used immediately or stored at 708C. The PCR pro-
ducts were electrophoresed in 1.8% agarose gels, dried
under vacuum, and placed into a PhosphorImager
(Molecular Dynamics, Amersham Biosciences, Buck-
inghamshire, UK) exposure cassette. Quantification
was carried out by ImageQuant software (Molecular
Dynamics).
Uterus Preparation and EFS
Uteri were removed from rats (250–350 g) on day 18,
20, or 22 of pregnancy. Muscle rings 0.5 cm long were
sliced from the uterine horns and mounted vertically
between two platinum electrodes in an organ bath
containing 10 ml de Jongh solution (in mM: 137 NaCl,
3 KCl, 1 CaCl2, 1 MgCl2, 12 NaHCO3, 4 NaH2PO4,
6 glucose, pH: 7.4). The organ bath was maintained at
378C and carbogen (95% O2þ 5% CO2) was bubbled
through it. After mounting, the rings were equilibrated
for about 1 hr before experiments were begun, with a
solution change every 15 min. The initial tension was
set to about 1.25 g, which had relaxed to about 0.5 g
by the end of equilibration. Maximum rhythmic con-
tractions were elicited with a digital, programmable
stimulator (ST-02, Experimetria Ltd. Budapest,
Hungary), using different values of pulse width (PW,
the duration of the electric field as a single stimulus)
and period time (PER, the time interval between two
stimuli) at 40 V. The applied PWs and PERs were
published earlier (Ga´spa´r et al., 2001). The tension of
the myometrial rings was measured with a gauge
transducer (SG-02, Experimetria U.K. Ltd.) and
recorded with an ISOSYS Data Acquisition System
(Experimetria U.K. Ltd.). Noncumulative concentra-
tion-response curves for the selective a1A-antagonist 5-
methylurapidil (5- MU; RBI, Budapest, Hungary), the
selective a1B-antagonist cyclazosine (RBI), and the
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selective a1D-antagonist BMY 7378 (RBI) were con-
structed in each experiment. The drug effects were
detected during another 240 sec. After this period, the
electric field was switched off and the tissues were
washed out three times and left to rest for 5 min.
Concentration-response curves were fitted and areas
under curves (AUCs) were evaluated and analyzed
statistically with the Prism 2.01 (GraphPad Software,
San Diego, CA) computer program. For statistical
evaluations, data were analyzed by ANOVA with the
Neuman–Keuls test.
RESULTS
The expression of a1A-AR mRNA increased from day
18–22 (Fig. 1a), while no a1B-ARmRNA expression was
detected by RT-PCR analysis. The expression of a1D-AR
mRNAwas highest on day 20 and then decreased to day
22 (Fig. 1b).
The electric field-stimulated contraction on days 18,
20, and 22 of pregnancy was inhibited concentration
dependently by the selective a1A-antagonist 5-MU
(Fig. 2a).
In the measured concentration range, the selective
a1B-antagonist cyclazosine had no significant action,
only its highest doses displayed weak inhibitory effects
on the stimulated contractions (Fig. 2b).
The a1D-antagonist BMY 7378 inhibited the contrac-
tion in a dose-dependent manner (Fig. 2c). The EC50
was established from the dose-dependence curves. The
a1A-AR antagonist 5-MU had EC50 values of
1.9 106–6.3106 M (Fig. 3a), while the EC50 of
the a1D-AR antagonist BMY 7378 lay in the range
4 106–3.6105 M (Fig. 3b).
A strong correlation was found between the a1A-
AR mRNA expression and the EC50 of 5-MU (r2¼
0.9712) (Fig. 4a), and between the a1D-AR mRNA
expression and the EC50 of BMY 7378 (r2¼ 0.9936)
(Fig. 4b).
DISCUSSION
The a-adrenergic part of the autonomic nervous
system exerts a great influence in the control of the
contractions of the pregnant myometrium.
In previous experiments, an a-AR dominance was
proved at the end of pregnancy (Zupko´ et al., 1997;
Ga´spa´r et al., 1998). The number of a1-ARs is known to
increase sharply in the last 6 hr of pregnancy, and
radioligand binding assays have shown that the num-
ber of a1A-ARs is increased by 88% at term. However,
limited data were earlier available concerning the
pharmacological reactivity of a1A-ARs and the roles of
the other a1-AR subtypes (Legrand et al., 1987; Limon-
Boulez et al., 1997).
The present study demonstrated the changes in the
a1A-, a1B-, and a1D-AR mRNA expressions on various
days of rat pregnancy with the RT-PCR technique. We
could detect no expression of a1B-AR in this period. The
selective a1B-antagonist cyclazosine exerted only weak
action in the measured concentration range, which
could be explained by some nonspecific activity at high
concentration.
The expression of the a1A-AR mRNA increased from
day 18 to 22, and the EFS studies revealed that the
a1A-antagonist 5-MU exhibited a well-balanced inhibi-
tory effect, without a significant decrease in efficacy or
effectivity at term.
We detected a significant increase in the expression
of a1D-AR mRNA on day 20, the expression then
decreasing to day 22. The a1D-antagonist BMY 7378
elicited a quite strong inhibitory effect, but we did not
observe significant changes in efficacy or effectivity on
days 18 and 20. At term, the inhibitory effect of BMY
Fig. 1. Changes in expression of uterine a1A- (a) and a1D- (b) adrenergic receptor mRNA in the late-
pregnant rat (*P< 0.05, **P<0.01, ***P<0.001).
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7378 was significantly decreased. Our findings suggest
that both a1A- and a1D-ARs are involved in the regu-
lation of the pregnant uterine contractility.
The increases in a1A-AR mRNA and the pharmaco-
logical reactivity demonstrate the important role of the
a1A-ARs near term. The a1A-ARs seem to play the major
role as regards the a1-subtypes in the late-pregnant
myometrium.
The a1A-AR antagonist 5-MU had EC50 values
(1.9106–6.3106 M) about one magnitude lower
than those of the a1D-AR antagonist, BMY 7378
(4106–3.6105 M). The RT-PCR and EFS findings
reveal a strong correlation between the mRNA expres-
sion and the pharmacological reactivity for the a1A- and
a1D-ARs. These correlations show that the syntheses of
a1A- and a1D-ARs are in harmony with the change in
pharmacological reactivity.
We consider that the strong correlation between the
receptor synthesis and pharmacological reactivity
could be beneficial compared to the b2-mimetics where
the process of receptor desensitization may decrease
the effectivity of these compounds (Yeagly et al., 1996;
Engelhardt et al., 1997). A similar effect was not
experienced in the case of a1-AR blockers.
Moreover, the side-effects of the a1-AR antagonists
during pregnancy might possibly be moderated or even
advantageous (e.g., pregnancy-induced hypertension).
CONCLUSIONS
Our findings suggest that both a1A- and a1D-ARs are
involved in the regulation of the pregnant uterine
contractility. We found a strong correlation between
the mRNA expression and the pharmacological re-
activity. The a1A-ARs seem to play the major role
as regards the a1-subtypes in the late-pregnant
myometrium.
Fig. 2. Inhibitory effects of the a1A-antagonist 5-MU (a), the a1B-
antagonist cyclazosine (b), and the a1D-antagonist BMY 7378 (c) on
electric field-stimulated contractions on different days of pregnancy in
the isolated rat myometrium.
Fig. 3. Changes in EC50 of the a1A-antagonist 5-MU (a) and the
a1D-antagonist BMY 7378 (b) on different day of pregnancy in vitro
(ns, not significant; **P< 0.01, ***P<0.001).
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In light of these facts, a1A-blockers might offer new
perspectives in tocolysis. However, further investiga-
tions are required, including thorough density mapping
of the a1-AR subtypes and clinical trials are planned for
the human myometrium.
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